PRC
KPTI icon

Pearl River Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Pearl River Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-79
Closed -$11K – 578
2018
Q4 		$11K Buy
+79
New +$13.3K 0.05% 521

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Pearl River Capital's KPTI Position: Q1 2019 in Review

Pearl River Capital sold out of Karyopharm Therapeutics (KPTI) in Q1 2019, closing a stake of 79 shares — an estimated $11K sold.

Pearl River Capital first reported a position in KPTI in Q4 2018 and held it in 1 quarter. The position peaked at $11K in Q4 2018. 108 funds tracked by Wall St. Rank hold KPTI as of Q1 2019.

  • Pearl River Capital reported no remaining Karyopharm Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Pearl River Capital sold 79 Karyopharm Therapeutics shares in Q1 2019, an estimated $11K.
  • Pearl River Capital first reported a position in Karyopharm Therapeutics in Q4 2018 and held it in 1 quarter.
  • Pearl River Capital's Karyopharm Therapeutics position peaked at $11K in Q4 2018.
  • 108 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.